You don't need to be signed in to read BMJ Blogs, but you can register here to receive updates about other BMJ products and services via our site.

Risks of NSAID Use after Myocardial Infarction

1 Apr, 15 | by Alistair Lindsay

Nonsteroidal anti-inflammatory drugs (NSAID) are frequently used as over-the-counter and prescription medications.  Although prior studies have raised concern about the cardiovascular safety of these medications, detailed information on the risk of these medications in patients after myocardial infarction (MI) is lacking. In this study, retrospective Danish National Patient Registry data was evaluated for all patients >30 years old, admitted with first myocardial infarction (MI) between 2002-2011 and who survived to 30 days post-discharge.  All claimed medications were identified for anti-platelet agents and NSAIDS and evaluated as a time-varying covariate in the analysis to ensure outcomes were properly allocated when patients were or were not exposed. more…

Erythropoietin fails to reduce myocardial damage in STEMI

28 May, 11 | by Alistair Lindsay

Patients who survive STEMI often go on to develop infarct expansion and myocardial thinning which can lead to heart failure and, ultimately, death.  In an attempt to limit this phenomenon, several agents have been proposed, amongst them erythropoietin.  In addition to its effects on red blood cell production, erythropoietin also stimulates angiogenesis and apoptosis, and several animal models have suggested that it can have a cardioprotective role in myocardial ischaemia.  Therefore the purpose of the REVEAL (Reduction of Infarct Expansion and Ventricular Remodelling With Erythropoietin After Large Myocardial Infarction) trial was to evaluate the safety and efficacy of a single intravenous bolus of erythropoietin alfa in patients with STEMI.  Cardiac Magnetic Resonance (CMR) was used to determine infarct size at 2-6 days after study medication administration, and then again 12 weeks later. more…

Does physical activity trigger cardiac events?

4 Apr, 11 | by Alistair Lindsay

Physical activity conveys many health benefits including a reduction in the chances of developing cardiovascular disease.  However, it has also been suggested that physical activity, as well as others acute exposures such as sexual activity and psychological stress, can actually trigger acute cardiac events. more…

Prioritising the triggers of myocardial infarction

4 Mar, 11 | by Alistair Lindsay

A number of factors have been associated with the onset of myocardial infarction, including physical exertion, drug abuse, heavy meals, stress, or increases in air pollution. Which of these triggers is the most important or relevant has not previously been investigated either at the population or the individual level. more…

New genetic loci for MI and atherosclerosis found

8 Feb, 11 | by Alistair Lindsay

Recent genome-wide association studies (GWAS) have identified several novel loci associated with coronary artery disease and myocardial infarction, however these represent only a small proportion of the inherited component of these disorders.  Furthermore, it is not clear whether these loci contribute to the development of atherosclerosis, or whether they may influence the stability of atherosclerotic plaque.  Therefore, this study was designed to investigate whether genetic factors predisposing to MI in patients with coronary atherosclerosis are distinct from those that associate with the presence of coronary atherosclerosis. more…

p53, microRNAs, and myocardial infarction

4 Jan, 11 | by Alistair Lindsay

MicroRNAs (miRNA) are short nucleotide chains that act as inhibitors of gene expression.  Specifically, miR-499 is a cardiac-abundant microRNA that can prevent cardiomyocyte apoptosis by targeting calcineurin-mediated activation of Drp1, an enzyme that normally results in fission of mitochondrial tubules into fragments.  miR-499 may therefore have a key role to play following myocardial infarction, as abnormal mitochondrial fission is involved in the initiation of apoptosis. more…

Normalisation of blood glucose levels following myocardial infarction predicts favourable in hospital outcome.

21 Jun, 09 | by Alistair Lindsay

Despite a strong association between elevated blood glucose levels and increased rates of mortality among patients hospitalised with acute myocardial infarction (AMI), the benefit of acutely lowering levels of blood glucose remains controversial. Several questions remain unanswered: more…

New MI diagnosis criteria, same old risk

17 Jan, 09 | by Alistair Lindsay

The traditional diagnosis of myocardial infarction (MI) used the World
Health Organization definition and required the concentration of a
cardiac biomarker to be above twice the upper limit of normal.
However, more recent guidelines have defined a troponin level above
the 99th percentile of normal as being diagnostic of MI. more…

Metabolic assays of ischaemia show early promise

14 Oct, 08 | by Alistair Lindsay

Metabolic technologies allow the profiling of low-molecular weight biochemicals such as amino acids, sugars, and lipids that are substrates and products in important biological processes, such as ischaemia.  To examine whether this techology could be used to allow earlier detection of myocardial ischaemia and infarction, Lewis et al. applied mass spectrometry-based metabolite profiling to 36 patients undergoing alcohol septal ablation for hypertrophic cardiomyopathy. more…

Latest from Heart

Latest from Heart

Cardiology Masterclasses

Cardiology Masterclasses